About Us

Hans received his Ph.D. in Biochemistry from the Swiss Federal Institute of Technology in Zurich, Switzerland (ETHZ) followed by Postdoctoral Training in Microbiology/Pathology at the University of Pennsylvania School of Dental Medicine (Philadelphia) and in Immunology at the Wistar Institute (Philadelphia, PA). He then joined the Univ. Pennsylvania School of Dental Medicine as a Research Assistant Professor in the Dept. of Pathology where he studied interactions of anaerobe bacteria with various human cell types, funded by a NIH Young Investigator Award. In 1991 Hans transitioned to the Diagnostic Industry and joined Pacific Biotech (San Diego, CA), an Eli Lilly subsidiary, as a Senior Scientist to develop an Influenza diagnostic assay. After the acquisition of PB by Quidel Corp. (San Diego, CA), Hans assumed various responsibilities in immunoassay development and led various groups as a Director of R&D. In 2001 he moved to Genzyme Diagnostics and led the San Diego R&D team as a Scientific R&D Director. In 2010, Hans joined DCN Diagnostics (Carlsbad, CA) as Vice President of Technology Development where he was responsible for contract assay development activities, education services, external support for grant applications, and he was awarded several SBIR grants. During his time at DCN, Hans was responsible for the feasibility and development of >100 different LFA programs. In 2022 Hans joined Biomerica Inc. (Irvine, CA) as Senior VP of R&D where he was leading the R&D team to develop point-of-care immunoassays. In January 2024 he started Artemis Dx with his former colleague, Bob Hudak, providing much needed support for the point-of-care assay community. For further information on Hans, click here.